Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
Z Kardiol ; 94(11): 742-7, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16258776

ABSTRACT

Treatment of in-stent restenosis (ISR) remains a therapeutic challenge since many pharmacological and mechanical approaches have shown disappointing results except for brachytherapy. Drug-eluting stents (DES) have been reported to effectively reduce ISR in de novo lesions. We studied 55 consecutive patients with ISR in native coronary arteries and 7 with ISR in saphenous vein grafts (SVG) with elective indication for percutaneous coronary intervention (PCI), who underwent successful implantation with DES. No in-hospital postprocedural major adverse cardiac events were observed. All but one patient (n=61) underwent an angiographic follow-up at 183+/-30 days. Grade of stenosis was assessed by quantitative coronary angiography (QCA) at index procedure and at control angiography. Restenosis (>50%) occurred in 5 patients (8.2%). Target vessel revascularization was performed in an additional 4 patients. Minimal intimal hyperplasia was observed in all segments covered by DES (late loss 0.08+/-0.37 mm, loss index 0.11+/-0.47). One patient suffered from subacute stent thrombosis due to discontinuation of clopidogrel medication. At six month follow-up two patients had died. Death was not related to a restenosis in the treated segment. Conclusion Our experiences with DES treatment of ISR lesions show good angiographic and clinical results at index procedure and at the 6 month follow-up with low sub acute thrombosis rate as compared with existing treatment modalities. Restenosis rate seems to be at least as low as reported for brachytherapy.


Subject(s)
Blood Vessel Prosthesis/adverse effects , Coronary Restenosis/drug therapy , Coronary Restenosis/etiology , Graft Occlusion, Vascular/drug therapy , Graft Occlusion, Vascular/etiology , Sirolimus/administration & dosage , Stents/adverse effects , Coronary Restenosis/diagnostic imaging , Drug Implants/administration & dosage , Equipment Design , Equipment Failure Analysis , Female , Follow-Up Studies , Graft Occlusion, Vascular/diagnostic imaging , Humans , Immunosuppressive Agents/administration & dosage , Male , Middle Aged , Radiography , Treatment Outcome
2.
Z Kardiol ; 93(3): 209-15, 2004 Mar.
Article in German | MEDLINE | ID: mdl-15024588

ABSTRACT

BACKGROUND: In patients with atrial septal defects of the secundum-type (ASD), exercise tolerance is reduced. Generally, ASD closure is recommended in symptomatic patients and in patients with a relevant left-to-right shunt (Qp/Qs > 1.5). Only few data are available concerning objective parameters of cardiopulmonary exercise capacity. The aim of this study was to evaluate exercise capacity as achieved by ergospirometry in adult patients with an ASD at baseline and in the long-term following transcatheter closure. METHODS AND RESULTS: Thirty consecutive patients (8 male; mean age 43.4 years; defect size 23.5 mm; pulmonary-to-systemic flow ratio (Qp/Qs) 1.94) performed exercise testing on a supine bicycle ergometer. At baseline, oxygen consumption at maximal exercise (VO(2) peak) was 14.3 ml/min kg, oxygen consumption at the anaerobic threshold (VO(2)-AT) was 11.2 ml/min/kg and maximal achieved workload was 86 Watt. At one and six months after ASD-closure, there was no relevant increase of the VO(2) peak, the VO(2)-AT or the maximal workload. After 12 months, there was a significant increase of the VO(2) peak (15.1 ml/min/kg, p = 0.049), the VO(2)-AT (13 ml/min/kg, p < 0.001) and the maximal workload (99 Watt, p < 0.01). An increase of the oxygen consumption at the anaerobic threshold (Delta VO(2) AT) could be seen in 24 out of 30 patients and was independent of shunt volume (Q(p)/Q(s) < or = 2, 1.95 ml/ min/kg; Q(p)/Q(s) > 2, 2.13 ml/min/ kg; ns), defect size (defect < or = 24 mm, 2.0 ml/min/kg; defect > 24 mm, 1.5 ml/min/kg; ns), age (age < or = 44 years, 1.97 ml/min/kg; age >44 years, 1.66 ml/min/kg; ns), gender (female 1.56 ml/min/ kg; male 1.91 ml/min/kg; ns) and of the existence of a residual shunt. Highly symptomatic patients had a tendency to have greater benefit from ASD-closure as compared to mildly symptomatic patients (NYHA 0/I 1.85 ml/min/kg; NYHA II 1.5 ml/min/ kg; NYHA III 2.7 ml/min/kg; ns). There was no correlation between shunt volume, shunt size, pulmonal arterial pressure and increase of the oxygen consumption at the anaerobic threshold (Delta VO(2) AT). CONCLUSION: There is no relevant improvement in exercise capacity early (1-6 months) after interventional ASD-closure, but late after ASD-closure (12 months) exercise capacity improves significantly. This improvement can be found in almost all patients independent of gender, age, symptoms, shunt volume and defect size.


Subject(s)
Exercise Test , Heart Septal Defects, Atrial/surgery , Physical Endurance/physiology , Postoperative Complications/diagnosis , Adolescent , Adult , Aged , Anaerobic Threshold/physiology , Cardiac Catheterization , Echocardiography , Female , Follow-Up Studies , Heart Septal Defects, Atrial/physiopathology , Humans , Male , Middle Aged , Oxygen/blood , Physical Exertion/physiology , Postoperative Complications/physiopathology , Prosthesis Implantation , Spirometry
3.
Fortschr Med ; 111(32): 513-6, 1993 Nov 20.
Article in German | MEDLINE | ID: mdl-8294078

ABSTRACT

METHODS: In 12 patients with inoperable malignant obstructive jaundice, percutaneous transhepatic biliary drainage was performed to decompensate the bile ducts. For a period of 7 days, the patients received a single daily i.v. dose of 1 g CFTX, and the serum and bile concentrations were measured at defined intervals. RESULTS: The dose sufficed to kill about 85% of the expected organisms. Although an accumulation of the substance as documented under conditions of normal bile flow was not demonstrable under cholestatic conditions, effective levels were nevertheless found in the bile and showed a tendency to increase with increasing bile flow.


Subject(s)
Bile/metabolism , Biliary Tract Neoplasms/blood , Ceftriaxone/pharmacokinetics , Cholangitis/blood , Cholestasis, Extrahepatic/blood , Aged , Aged, 80 and over , Biliary Tract Neoplasms/drug therapy , Bilirubin/blood , Ceftriaxone/therapeutic use , Cholangitis/drug therapy , Cholestasis, Extrahepatic/drug therapy , Female , Humans , Infusions, Intravenous , Male , Metabolic Clearance Rate/physiology , Microbial Sensitivity Tests , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...